QL555

QL555 is a preclinical-stage bispecific T-cell engager (BiTE) being developed by QLSF Biotherapeutics for the treatment of solid tumors. The drug is engineered using QLSF's proprietary TECOS (T-cell engager) platform technology, which is designed to develop next-generation T-cell engagers that modulate the tumor microenvironment and enhance anti-tumor immune responses. As a bispecific antibody, QL555 is designed to bridge T cells and tumor cells by simultaneously binding to a tumor-associated antigen and the CD3 complex on T cells, thereby triggering T-cell-mediated cytotoxicity against the cancer cells. While the specific tumor-associated target for QL555 has not been publicly disclosed, the candidate is part of a broader pipeline of antibody-based therapeutics targeting solid and hematological malignancies.